A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA
- Sponsor
- University of Illinois at Chicago
- Study ID
- NCT05504954
- Status
- Completed
Conditions
- Hiv
- Sexually Transmitted Infection
Eligibility Criteria
- Sex
- FEMALE
- Age
- 15 Years - 19 Years
- Healthy Volunteers
- Accepted
Interventions
- IMARA-SA (intervention group) — BEHAVIORALThe IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
- Health promotion control group — BEHAVIORALThe health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
Study Details
Programs which go beyond individual-level behavior change to reduce HIV and STI infections among adolescent girls and young women in sub-Saharan Africa are essential to meet global HIV targets. Informed, Motivated, Aware and Responsible Adolescents and Adults- South Africa (IMARA-SA) is an evidence-based HIV-prevention intervention for adolescent girls and young women (AGYW) and their female caregivers, which has been adapted for a South African audience. This pilot study will assess feasibility in preparation for a randomized controlled trial (RCT). Additionally, the pilot will examine the preliminary effectiveness of IMARA-SA in reducing sexually transmitted infections (STI) and increasing uptake of HIV testing and counseling (HTC) and pre-exposure prophylaxis (PrEP) at follow-up among AGYW. About 60 AGYW-FC dyads will be enrolled and randomized to IMARA-SA or a health-promotion control arm. Following randomization, the dyads will participate in an \~2-day group workshop (\~10 hours), which includes joint and separate mother and daughter activities. AGYW and FC will complete baseline assessments and follow-up assessments approximately 6 months later. Assessments will include surveys, STIs testing (for chlamydia and gonorrhea), and uptake of HTC and a 1-month PrEP prescription. Additionally, the intervention's implementation (e.g., acceptability) will be explored.
Key Dates
- Start date
- Oct 26, 2019
- Status verified
- Aug 2025
- Primary completion
- May 15, 2021
- Completion
- May 15, 2021
Study Design
- Enrollment
- 61 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: IMARA-SA intervention armParticipants randomized to the IMARA-SA arm will receive the IMARA-SA intervention (i.e., the intervention group).
- Experimental: Health promotion control armParticipants randomized to the health promotion control arm will receive the health promotion intervention (i.e., the control group).
Primary Outcome Measure
Number of AGYW Who Tested Positive for a Sexually Transmitted Infection (STI) [ Time Frame: 8-17 months post baseline ]
Related Studies
- Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIVRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Washington D.C., District of Columbia
- Viral Load in Blood and Lymph Tissues in People Living With HIVRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressorsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland